Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.

• Autores: Carles Pericay Pijaume, Pilar Escudero Emperador, Romà Bastus Piulats, Juan Manuel Campos Cervera, Gaspar Esquerdo Galiana
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 13, Nº. 1, 2011, págs. 61-66
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Aim Advanced pancreatic cancer has a bad prognosis, with a median overall survival (OS) no longer than 4�6 months. Since the end of last century, monotherapy with gemcitabine has remained the elective therapy, but new schedules are needed in order to improve these results. We aim to evaluate the efficacy of tegafur and levofolinic acid (LV) associated with gemcitabine, as well as its toxicity, progressionfree survival and OS in advanced pancreatic cancer.

    Patients and methods An open-label, multicentric, prospective, non-controlled trial was carried out on patients with advanced or disseminated pancreatic cancer. Gemcitabine 1250 mg/m2 was administered on the 1st and 8th days of the cycle, tegafur 750 mg/m2/day for 21 consecutive days and LV 25 mg/day continuously, every 28 days, with a maximum of six cycles. The primary variable was tumour overall response rate (ORR). Secondarily, time to progression (TTP), OS and scheme toxicity were determined.

    Results Forty patients were recruited; the male/female ratio was 30:10, with a mean age of 61 years. Forty percent had a Karnofsky index of 90% or 100%. Only 11 patients (27%) completed the six cycles of treatment, but more than 50% received three or more cycles. Dose intensity was 89.56% for gemcitabine and 87.36% for tegafur. Efficacy ORR was 22.5% (CI 95%, 6�37%). TTP was 3.87 months (CI 95%, 2.1�5.6), time to treatment failure was 2.97 months (CI 95%, 2.43�4.67) and OS 6.3 months (CI 95%, 4�7). The chemotherapeutic combination was well accepted; most haematologic and non-haematologic toxicities were grade 1 or 2. The most prevalent grade 3/4 toxicities were asthenia (30%), liver biochemistry disorders (25%), diarrhoea (15%) and stomatitis (12%).

    Conclusions The administration of gemcitabine, associated with oral tegafur and leucovorin, has activity against advanced pancreatic cancer, with an adequate toxicity profile.